Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06378892
Title A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)
Acronym ALK-PPL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Centro di Riferimento Oncologico - Aviano
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST